Durham, NC – Tergus Pharma, a commercial scale Contract Development and Manufacturing Organization (CDMO) of semi-solid and liquid dosage forms, announced today that Michael Kane has been appointed as the Company’s new Chief Executive Officer. Dr. Vijendra Nalamothu, Tergus’ founder and who has served as Chairman & CEO since 2012, will assume the role of Executive Chairman & Chief Scientific Officer.
“We are thrilled to welcome Michael Kane as the new CEO of Tergus and I am confident that he will continue the scientific excellence and transformation at Tergus. As Executive Chairman I will be able to focus more on our growth strategy and related scientific efforts, while Kane will be empowered as CEO to manage overall corporate operations. I look forward to working closely with Michael in my role as Executive Chairman & Chief Scientific Officer to help write Tergus Pharma’s next chapter.” said Dr. Nalamothu.
Mr. Kane joins Tergus with over thirty years of manufacturing experience and commercial scale operations. Prior to joining Tergus, Mr. Kane was in company leadership roles as the CEO and COO on middle market pharmaceutical and healthcare product companies that developed and manufactured topical, solid, soft gel, oral liquid and powder dosage forms across branded Rx, generic, OTC and medical nutrition segments. He was also an Operating Partner and board director at Blue Point Capital Partners, a private equity firm based in Cleveland, Ohio. Mr. Kane’s prior experience also includes operational leadership positions at Novartis and Abbott Laboratories.
Mr. Kane stated “I am pleased to join the Tergus management team at an important inflection point in the company history. I was attracted to the role at Tergus because of their deep scientific expertise, their excellent facility, and impressive roster of clients that have developed over the past ten years. It is clear the future is very bright for the organization, and I look forward to working with employees and customers to build a leading topical CDMO.”